School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Int J Mol Sci. 2023 Jul 2;24(13):11004. doi: 10.3390/ijms241311004.
Inflammatory bowel disease (IBD) is a complex multifactorial chronic inflammatory disease, that includes Crohn's disease (CD) and ulcerative colitis (UC), having progressively increasing global incidence. Disturbed intestinal flora has been highlighted as an important feature of IBD and offers promising strategies for IBD remedies. A brief overview of the variations occurring in intestinal flora during IBD is presented, and the role of the gut microbiota in intestinal barrier maintenance, immune and metabolic regulation, and the absorption and supply of nutrients is reviewed. More importantly, we review drug research on gut microbiota in the past ten years, including research on clinical and natural drugs, as well as adjuvant therapies, such as Fecal Microbiota Transplantation and probiotic supplements. We also summarize the interventions and mechanisms of these drugs on gut microbiota.
炎症性肠病(IBD)是一种复杂的多因素慢性炎症性疾病,包括克罗恩病(CD)和溃疡性结肠炎(UC),其全球发病率呈逐渐上升趋势。肠道菌群紊乱已被强调为 IBD 的一个重要特征,并为 IBD 的治疗提供了有前景的策略。本文简要概述了 IBD 期间肠道菌群的变化,并综述了肠道微生物群在肠道屏障维持、免疫和代谢调节以及营养物质的吸收和供应中的作用。更重要的是,我们回顾了过去十年中关于肠道微生物群的药物研究,包括临床和天然药物以及辅助治疗,如粪便微生物群移植和益生菌补充剂的研究。我们还总结了这些药物对肠道微生物群的干预和作用机制。